Skip directly to content

Investors

Selventa is funded by industry-leading investors, including Flagship Ventures and Pappas Ventures. As a proud member of these families, Selventa has benefited from their guidance and insight.

 

 

 

Realizing entrepreneurial innovation is the mission of Flagship Ventures. The firm operates through two synergistic units: VentureLabs™ which invents and launches transformative companies, and Venture Capital, which finances and develops innovative, early-stage companies. Founded in 2000, and based in Cambridge, Massachusetts, Flagship Ventures manages over $900 million in capital. The Flagship team is active in three principal business sectors: therapeutics, health technologies and sustainability/clean technology. Past successful Flagship portfolio companies include: Accuri Cytometers (acquired by Becton, Dickinson and Company), Adnexus (acquired by Bristol-Myers Squibb), Hypnion (acquired by Eli Lilly), Agios (NASDAQ: AGIO), AVEO (NASDAQ: AVEO), BG Medicine (NASDAQ: BGMD), Receptos (NASDAQ: RCPT), Tetraphase (NASDAQ: TTPH), and Morphotek (acquired by Eisai). Additional notable portfolio companies include: Affinnova, BIND Therapeutics, Joule Unlimited, Quanterix, and Moderna Therapeutics. For more information, please visit www.flagshipventures.com.

Founded in 1994, Pappas Ventures only invests in the life sciences – biotechnology, specialty pharmaceuticals, drug delivery, medical devices and related ventures. Each partnership or long-term collaboration brings promising technologies to commercial application – from concept to commerce. Pappas has helped more than 50 organizations turn breakthrough ideas into market-leading companies.